ArticleNature communications2026
Thromboxane A2 receptor signalling amplifies osteoclastogenesis in rheumatoid arthritis through ACSL1 associated mitochondrial oxidative metabolism.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activated platelets contribute to inflammation in rheumatoid arthritis, but how platelet-derived signals promote bone erosion remains poorly understood. Here we show that thromboxane A2, a major mediator released by activated platelets, promotes the formation of bone-resorbing osteoclasts through the thromboxane A2 receptor. Markers of thromboxane A2 biosynthesis are increased in patients with rheumatoid arthritis, while pharmacological inhibition or genetic loss of its receptor suppresses osteoclastogenesis in mouse cells and mice. Integrated molecular analyses reveal that thromboxane A2 receptor signalling supports osteoclastogenesis by increasing fatty acid oxidation and acetyl-coenzyme A supply needed for mitochondrial energy metabolism, involving peroxisome proliferator-activated receptor gamma coactivator 1 beta, peroxisome proliferator-activated receptor gamma and acyl-coenzyme A synthetase long-chain family member 1. In male mice, receptor inhibition or genetic deletion reduces osteoclast accumulation and bone destruction. These findings identify thromboxane A2 signalling as a driver of inflammatory bone erosion and a potential therapeutic target in rheumatoid arthritis.
Indexed as
Identifiers
42881186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.